Research Analysts Set Expectations for IPSC Q3 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Analysts at William Blair issued their Q3 2026 earnings estimates for shares of Century Therapeutics in a research note issued on Thursday, March 20th. William Blair analyst S. Corwin forecasts that the company will post earnings per share of ($0.47) for the quarter. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share.

Several other research firms have also recently issued reports on IPSC. Guggenheim restated a “buy” rating on shares of Century Therapeutics in a report on Wednesday, January 22nd. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Finally, Piper Sandler cut their price objective on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a report on Thursday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $6.00.

Century Therapeutics Price Performance

NASDAQ:IPSC opened at $0.55 on Friday. Century Therapeutics has a 1-year low of $0.52 and a 1-year high of $5.24. The firm has a 50 day simple moving average of $0.75 and a 200-day simple moving average of $1.17. The firm has a market cap of $46.77 million, a PE ratio of -0.30 and a beta of 1.75.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.02. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The firm had revenue of $4.18 million for the quarter, compared to analysts’ expectations of $0.67 million.

Hedge Funds Weigh In On Century Therapeutics

Large investors have recently modified their holdings of the stock. Marshall Wace LLP acquired a new stake in shares of Century Therapeutics during the 4th quarter valued at approximately $36,000. Jane Street Group LLC raised its holdings in shares of Century Therapeutics by 166.2% during the fourth quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after purchasing an additional 29,992 shares during the period. Two Sigma Advisers LP bought a new position in shares of Century Therapeutics in the 4th quarter worth about $52,000. Sei Investments Co. acquired a new position in shares of Century Therapeutics in the 4th quarter valued at about $53,000. Finally, Barclays PLC grew its position in shares of Century Therapeutics by 283.6% during the 3rd quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after buying an additional 45,797 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.